Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view).
Shares of Takeda Pharmaceutical are down 1.28% at $18.57. The company is worth $59.30B, number 271 out of 300 on our list.
Over the past 52 weeks it has traded between $12.77 and $19.10, so it sits 2.8% below the top of that range. Holders are ahead 29.1% over twelve months, and up 18.1% across the last three months.
On the chart it holds above both the 50-day ($17.82) and 200-day ($16.91) moving averages; RSI is 64, and the last 30 sessions moved at roughly 19% annualized volatility.
Revenue for the quarter ended Jun 2026 was ¥1.22T, up 10.2% from a year earlier, with ¥113.26B of net profit (a -3.5% margin).
1 analysts follow the stock and the average call is "buy". The mean target, $44.27, sits 138.4% over where the stock trades.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Takeda is a Japanese drugmaker with products in gastrointestinal, rare disease, neuroscience and oncology, and plasma-derived therapies.
What tends to move it. Patent expiry of Vyvanse and growth of newer products are the central issues.
Written by hand by the BeStock desk and revised when a business changes. See how we work. Spot something out of date? Tell us.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +0.5% | Bullish |
| Price vs 50-day average | +4.2% | Bullish |
| Price vs 200-day average | +9.8% | Bullish |
| 50-day vs 200-day | 50d above 200d | Bullish |
| RSI (14) | 64.1 | Bullish |
| MACD (12,26,9) | 0.33 | Bullish |
| Bollinger band position | 56% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Sep 24, 2026 1:10 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 300 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A row is left out when the measure does not apply, such as yield for a stock that pays no dividend.
Latest reported quarter: Q1, ended Jun 2026 · reported in JPY
Quarter 2027/Q1
"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.
Multiples measured against the stock's own five-year history
Near the bottom of its 5-year range · 3rd percentile, 5-year average 39.2x
Near the top of its 5-year range · 97th percentile, 5-year average 1.0x
#1538 of 5304 stocks by PB (1 = cheapest)
Near the top of its 5-year range · 94th percentile, 5-year average 1.6x
#2386 of 5143 stocks by PS (1 = cheapest)
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Who holds it, who is betting against it, and where the big money is moving
Net of large-order buying minus selling, in USD. Over this window: +$515.1K (12 inflow days, 8 outflow days).
Across the full calendar years shown, the annual payout grew by roughly 2.5% a year.
$18.57 is the latest print for TAK, a move of -1.28% against yesterday's close of $18.81. Today's low and high so far: $18.51 and $18.74.
Equity value comes to $59.30B at the current price. By that measure it is number 271 of the 300 names in our coverage.
The year's floor is $12.77 and the ceiling $19.10. Shares are 2.8% away from that ceiling.
It does. Payouts over the past twelve months work out to a 3.22% yield; the latest ex-dividend date was March 31, 2026.
Of 1 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $44.27, with the most cautious at $44.27 and the most optimistic at $44.27.
Takeda is a Japanese drugmaker with products in gastrointestinal, rare disease, neuroscience and oncology, and plasma-derived therapies.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.